Alison L. Hannah
CIK: 0001645600
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jul 8, 2026RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct24.4K shares- - May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct5.8K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Exercise(M)Direct12.3K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Award(A)Direct12.3K shares- - Jun 1, 2025NEO
NEOGENOMICS INC
Exercise(M)DirectRestricted Stock Unit
12.3K shares- - May 23, 2025RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct2.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 8, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 24,400 | - | $0 | Direct |
| May 15, 2026 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 5,750 | - | $0 | Direct |
| Jun 1, 2025 |  NEO NEOGENOMICS INC | Exercise(M) | 12,254 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Award(A) | 12,254 | - | - | Direct |
| Jun 1, 2025 | NEO NEOGENOMICS INC | Exercise(M) Restricted Stock Unit | 12,254 | - | - | Direct |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 2,500 | - | - | Direct |
1-6 of 6 transactions
About HANNAH ALISON L.
HANNAH ALISON L. (SEC CIK 0001645600) files insider reports with the SEC as EVP, Chief Medical Officer of RIGEL PHARMACEUTICALS INC (RIGL) and Director of NEOGENOMICS INC (NEO).
Signal8 holds 5 ownership filings by HANNAH ALISON L., all Form 4s, filed between May 28, 2025 and Jul 10, 2026. Those filings report 6 transactions, from May 23, 2025 to Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on HANNAH ALISON L.'s filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by HANNAH ALISON L.
- Jul 8, 2026: Grant or award of RIGL shares (Form 4, code A).
- May 15, 2026: Grant or award of RIGL shares (Form 4, code A).
- Jun 1, 2025: Option exercise of NEO shares (Form 4, code M).
- Jun 1, 2025: Grant or award of NEO shares (Form 4, code A).
- Jun 1, 2025: Option exercise of NEO derivative securities (Form 4, code M).
Other insiders filing for RIGEL PHARMACEUTICALS INC (RIGL)
- Schorno Dean L, EVP & Chief Financial Officer
- Santos David A, EVP, Chief Commercial Officer
- RODRIGUEZ RAUL R, CEO, President
- Furey Raymond J., EVP, GC, CCO & Corp Sec
- Ali-Jackson Kamil, Director
- Rojkjaer Lisa, EVP, Chief Medical Officer